Dual Inhibition of Bruton's Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias by Eide, Christopher A., Kurtz, Stephen E, Kaempf, Andy, Tognon, Cristina E., Mori, Motomi, Gordon, Max J., Tyner, Jeffrey W., Danilov, Alexey V, Druker, Brian J.

Get full text

Characterizing Population Heterogeneity and Signaling Changes in Chronic Myeloid Leukemia Stem and Progenitor Cells upon Combined Treatment with Imatinib and MEK Inhibitors Using Q... by Reister Schultz, Anna, Jacob, Thomas, Eide, Christopher A., Savage, Samantha L, Mori, Motomi, Tyner, Jeffrey W., Tognon, Cristina E., Vu, Tania Q., Druker, Brian J.

Get full text

Combining p38MAPK Inhibitors with a Second Targeted Agent Enhances Blockade of Inflammatory Signaling-Mediated Survival in Acute Myeloid Leukemia Cells by Kurtz, Stephen E, Eide, Christopher A., Dubey, Narain P., Kaempf, Andy, McWeeney, Shannon K., Tognon, Cristina E., Mori, Motomi, Druker, Brian J., Tyner, Jeffrey W., Agarwal, Anupriya

Get full text

Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort by Bottomly, Daniel, Long, Nicola, Yang, Fei, Lee, Tiffany, Borate, Uma, Wilmot, Beth, DuVall, Adam S, Monteblanco, Andrea, Thiel-Klare, Karina, Dewson, Gabby, Press, Richard D., Tognon, Cristina E., Druker, Brian J., Tyner, Jeffrey W., McWeeney, Shannon K., Agarwal, Anupriya

Get full text

Abstract LT022: The AML microenvironment catalyzes a step-wise evolution to gilteritinib resistance by Joshi, Sunil K., Nechiporuk, Tamilla, Bottomly, Daniel, Piehowski, Paul, Reisz, Julie A., Pittsenbarger, Janét, Kaempf, Andy, Gosline, Sara J.C., Wang, Yi-Ting, Liu, Tao, Tognon, Cristina E., D’Alessandro, Angelo, Tyner, Jeffrey W., McWeeney, Shannon K., Rodland, Karin D., Druker, Brian J., Traer, Elie

Get full text

Evolution of Gilteritinib Resistance from Residual Disease to Relapse by Joshi, Sunil K, Nechiporuk, Tamilla, Bottomly, Daniel, Piehowski, Paul, Reisz, Julie, Pittsenbarger, Janét, Gosline, Sara J, Kaempf, Andy, Wang, Yi-Ting, Moon, Jamie, Babur, Özgün, Watanabe-Smith, Kevin M, Demir, Emek, Tao, Liu, Tognon, Cristina E., D'Alessandro, Angelo, Tyner, Jeffrey W., McWeeney, Shannon K., Rodland, Karin, Druker, Brian J., Traer, Elie

Get full text

A Novel, Oncogenic CSF2RB Mutation Found in a Primary Leukemia Sample Results in Constitutive Signaling, Increased Receptor Stability, and Formation of Intermolecular Complexes by Watanabe-Smith, Kevin M, Tognon, Cristina E., Tyner, Jeffrey W., Druker, Brian J., Agarwal, Anupriya

Get full text

Novel Method to Perform Functional Drug Screens on Frozen Primary Leukemia Samples by Degnin, Michelle, Tarlock, Katherine, Agarwal, Anupriya, Meshinchi, Soheil, Tognon, Cristina E., Druker, Brian J.

Get full text

High-Throughput Validation of Mutations Identified in Primary Leukemia Cells by Degnin, Michelle, Tognon, Cristina E., Eide, Christopher A., Wilmot, Beth, McWeeney, Shannon K., Bottomly, Daniel, Smith, Rebecca, Druker, Brian J.

Get full text

Identification of Targeted Therapies for Rare Adult Mature T-Cell Leukemia Using Functional Ex Vivo Screening of Primary Patient Samples by Borate, Uma, Norris, Brianna A., Lo, Pierrette, Tognon, Cristina E., Junio, Brian, Tyner, Jeffrey W., Druker, Brian J.

Get full text

Identification of targeted therapies for rare adult mature T‐cell leukemia using functional ex vivo screening of primary patient samples by Borate, Uma, Norris, Brianna A., Lo, Pierrette, Tognon, Cristina, Tyner, Jeffrey, Spurgeon, Stephen

Get full text

Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML by White, Brian S., Khan, Suleiman A., Ammad-ud-din, Muhammad, Potdar, Swapnil, Mason, Mike J, Tognon, Cristina E., Druker, Brian J., Heckman, Caroline A, Kallioniemi, Olli, Kurtz, Stephen E, Porkka, Kimmo, Tyner, Jeffrey W., Aittokallio, Tero, Wennerberg, Krister, Guinney, Justin

Get full text

Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study by Tyner, Jeffrey W., Druker, Brian J., Kurtz, Stephen E, Tognon, Cristina E., Drusbosky, Leylah M., Vidva, Robinson, Narvekar, Yugandhara, Agrawal, Ashish Kumar, Gera, Saji, Prasad, Samiksha Avinash, Shyamasundar, Vijayashree P, Tunwer, Gaurav Singh, Abbasi, Taher, Vali, Shireen, Cogle, Christopher R.

Get full text

Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study by Tyner, Jeffrey W., Druker, Brian J., Tognon, Cristina E., Kurtz, Stephen E, Drusbosky, Leylah M., Sahu, Diwyanshu, Vidva, Robinson, Kapoor, Shweta, Azam, Humera, Kumar, Rajeev, Chickdipatti, Padmagiri G, Raveendaran, Nithya T, Gopi, Reshma P, Abbasi, Taher, Vali, Shireen, Cogle, Christopher R.

Get full text

The AML microenvironment catalyzes a step-wise evolution to gilteritinib resistance by Joshi, Sunil K., Nechiporuk, Tamilla, Bottomly, Daniel, Piehowski, Paul D., Reisz, Julie A., Pittsenbarger, Janét, Kaempf, Andy, Gosline, Sara J. C., Wang, Yi-Ting, Hansen, Joshua R., Gritsenko, Marina A., Hutchinson, Chelsea, Weitz, Karl K., Moon, Jamie, Cendali, Francesca, Fillmore, Thomas L., Tsai, Chia-Feng, Schepmoes, Athena A., Shi, Tujin, Arshad, Osama A., McDermott, Jason E., Babur, Ozgun, Watanabe-Smith, Kevin, Demir, Emek, D’Alessandro, Angelo, Liu, Tao, Tognon, Cristina E., Tyner, Jeffrey W., McWeeney, Shannon K., Rodland, Karin D., Druker, Brian J., Traer, Elie

Get full text

Combining the Allosteric ABL1 Inhibitor Asciminib (ABL001) with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Compound Mutants by Eide, Christopher A., Zabriskie, Matthew S., Savage, Samantha L., Antelope, Orlando, Vellore, Nadeem A., Than, Hein, Reister Schultz, Anna, Clair, Phillip M., Bowler, Amber D., Pomicter, Anthony D., Yan, Dongqing, Senina, Anna V., Wang, Qiang, Kelley, Todd W., Szankasi, Philippe, Heinrich, Michael C., Tyner, Jeffrey W., Rea, Delphine, Cayuela, Jean-Michel, Kim, Dong-Wook, Tognon, Cristina E., O'Hare, Thomas, Druker, Brian J., Deininger, Michael W.

Get full text

Expression and stability of hypoxia inducible factor 1α in osteosarcoma by El Naggar, Amal, Clarkson, Paul, Zhang, Fan, Mathers, Joan, Tognon, Cristina, Sorensen, Poul H.

Get full text

Abstract 3883: Gene expression predicts ex vivo drug sensitivity in acute myeloid leukemia by White, Brian S., Khan, Suleiman A., Ammad-ud-din, Muhammad, Potdar, Swapnil, Mason, Mike J., Tognon, Cristina E., Druker, Brian J., Heckman, Caroline A., Kallioniemi, Olli P., Kurtz, Stephen E., Porkka, Kimmo, Tyner, Jeffrey W., Aittokallio, Tero, Wennerberg, Krister, Guinney, Justin

Get full text

Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia by Agarwal, A, MacKenzie, R J, Eide, C A, Davare, M A, Watanabe-Smith, K, Tognon, C E, Mongoue-Tchokote, S, Park, B, Braziel, R M, Tyner, J W, Druker, B J

Get full text

Combining the Allosteric ABL1 Tyrosine Kinase Inhibitor ABL001 with ATP-Competitive Inhibitors to Suppress Resistance in Chronic Myeloid Leukemia by Eide, Christopher A., Savage, Samantha L., Heinrich, Michael C., Reister Schultz, Anna M., Tyner, Jeffrey W., Tognon, Cristina E., Druker, Brian J.

Get full text